Top

Published in:

01-08-2019 | Glucocorticoid | Case Report

Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series

Authors: Jacqueline N. Poston, Terry B. Gernsheimer

Published in: International Journal of Hematology | Issue 2/2019

Abstract

A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These patients were previously treated with a median of 6 therapies. One patient elected to discontinue both medications despite persistent thrombocytopenia. The remaining 9 patients continued on the combination of prednisone (doses 5 mg every other day to 10 mg daily) and a TPO-RA. Combination therapy with low dose glucocorticoid and a TPO-RA may be an option for patients unresponsive to a TPO-RA alone.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23. https://doi.org/10.1111/bjh.12260.CrossRefPubMed

Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45. https://doi.org/10.1182/blood-2012-04-425512.CrossRefPubMed

Rashidi A, Blinder MA. Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review. J Clin Pharm Ther. 2016;41(5):453–8. https://doi.org/10.1111/jcpt.12421.CrossRefPubMed

Arnold DM, Nazi I, Santos A, Chan H, Heddel NM, Warkentin TE, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29–31. https://doi.org/10.1182/blood-2009-06-222448.CrossRefPubMed

Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagul Fibrinolysis. 2012;23(4):331–4. https://doi.org/10.1097/MBC.0b013e3283513a97.CrossRefPubMed

Yoon JS, Lee YJ, Baek DW, Park HY, Park BE, Moon JH, et al. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. Korean J Intern Med. 2018;33(2):435–7. https://doi.org/10.3904/kjim.2015.252.CrossRefPubMed

Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus. 2014;12(Suppl 1):s149–50. https://doi.org/10.2450/2013.0289-12.CrossRefPubMedPubMedCentral

Gomez-Almaguer D, Herrera-Rojas MA, Jaime-Perez JC, Gomez-De Leon A, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123(25):3906–8. https://doi.org/10.1182/blood-2014-01-549360.CrossRefPubMed

Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351–8.PubMed

10.

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65. https://doi.org/10.1517/14740338.2016.1140743.CrossRefPubMed

11.

Carpenedo M, Cantoni S, Coccini V, Pogliani EM, Cairoli R. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. Eur J Haematol. 2016;97(1):101–3. https://doi.org/10.1111/ejh.12733.CrossRefPubMed

12.

Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood. 1978;51(5):771 LP–779.

13.

Mizutani H, Furubayashi T, Imai Y, Kashiwagi H, Honda S, Take H, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW × BXSB) F1. Blood. 1992;79(4):942–7.PubMed

14.

Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974–80. https://doi.org/10.1056/NEJM198904133201505.CrossRefPubMed

Title: Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series
Authors: Jacqueline N. Poston
Terry B. Gernsheimer
Publication date: 01-08-2019
Publisher: Springer Japan
Keywords: Glucocorticoid
Thrombocytopenia
Published in: International Journal of Hematology / Issue 2/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-019-02638-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors

Familial case of hereditary Pelger-Huët anomaly

Epigenetic abnormalities and therapies for hematological malignancies

Hereditary spherocytosis caused by copy number variation in SPTB gene identified through targeted next-generation sequencing

Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome

Deregulated Polycomb functions in myeloproliferative neoplasms

Keynote webinar | Spotlight on antibody–drug conjugates in cancer